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Abstract Promoter activation in the expression of phospholipid
hydroperoxide glutathione peroxidase (PHGPx) gene in human
epidermoid carcinoma A431 cells was studied in the present
investigation. Luciferase reporter assays with plasmids carrying
a 400 bp of the promoter DNA were performed to analyze the
regulatory element in the proximal promoter of human PHGPx
gene. Transient transfection with a series of 5P-deletion and
internal truncation mutants showed that the 5P-flanking region
spanning from 3212 to 3121 bp was important for the basal
expression of PHGPx gene in A431 cells. A region from 3170 to
3140 bp was protected in DNase I footprinting assays and bound
the nuclear proteins in electrophoretic mobility shift assays. This
region, denoted FP3, contains the consensus recognition sites for
AP-2, CCAAT-box and CRE. The oligonucleotide competitor
with the mutation at CCAAT-box could not eliminate the nuclear
protein binding in gel-shift assay and the site-directed mutagen-
esis at the CCAAT-box decreased the luciferase activity of
PHGPx promoter for approximate 50% in reporter gene assays.
Competition experiments indicate that the binding of nuclear
factor to the FP3 region was abolished by oligodeoxyribonucleo-
tide corresponding to NF-Y/CP1 binding site to a greater extent
than by those corresponding to sites for CTF/NFI and C/EBP.
Taken together, the CCAAT-box in the promoter ranging from
3156 to 3151 bp, bound to NF-Y/CP1, was essential for the
basal expression of human PHGPx gene in A431 cells.
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1. Introduction
Oxidative stress is associated with a disturbance in the re-
active oxygen species-antioxidant balance in favor of the for-
mer [1,2]. Many of the reactive oxygen species are involved in
the oxidative damage in a number of physiological and path-
ophysiological phenomena and processes as diverse as in£am-
mation, aging, carcinogenesis, drug action and drug toxicity.
The reactive oxygen species may be formed from polyunsatu-
rated fatty acids either by an enzymatic or by a non-enzymatic
oxygenation [3]. Reduction of the reactive oxygen species can
be achieved either by the inhibition of lipid oxygenation en-
zymes or by the interception of free radicals by antioxidants
and some antioxidation enzymes such as superoxide dismu-
tase, catalase and glutathione peroxidase.
Lipoxygenases and fatty acid cyclooxygenases are the major
enzymes involved in the metabolism of polyunsaturated fatty
acids including arachidonic acid [4]. In studying the regulation
of arachidonate metabolism in human epidermoid carcinoma
A431 cells, we previously reported a putative inhibitor of 12-
lipoxygenase, which masked the biosynthesis of 12(S)-hydrox-
yeicosatetraenoic acid in intact cells [5]. The putative inhibitor
in A431 cells was puri¢ed to a 22 kDa protein [6] whose
sequence data matched the cDNA sequence of human phos-
pholipid hydroperoxide glutathione peroxidase (PHGPx) [7].
So far, ¢ve selenium-dependent glutathione peroxidases have
been identi¢ed [8^12]. Among these isozymes, PHGPx is
unique in its substrate speci¢city because it can interact with
lipophilic substrates including the peroxidized phospholipids
and cholesterol and reduce these hydroperoxides to hydroxide
compounds [13,14]. PHGPx exists ubiquitously in all tissues,
but highly expresses in testis [15]. However, the high expres-
sion of PHGPx in testis is not directly regulated by testoster-
one [16].
In the present study, the functional promoter sequence in
human PHGPx gene for the basal expression in A431 cells
was analyzed. With the aid of in vitro DNase I footprinting
study, electrophoretic mobility shift assay and site-directed
mutagenesis, the CCAAT-box residing at 3155 to 3151 bp
in the promoter region, bound by the nuclear factor NF-Y/
CP1, was demonstrated to be essential for the transcriptional
activation of human PHGPx gene in A431 cells. This is the
¢rst demonstration of CCAAT-box mediating the expression
of human PHGPx gene in cancer cells.
2. Materials and methods
2.1. Reagents
[K-32P]dCTP (3000 Ci/mmol) and [Q-32P]ATP (5000 Ci/mmol) were
purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).
Polyvinyl alcohol, HEPES and o-nitrophenyl L-galactopyranoside
were from Sigma (St. Louis, MO, USA). Wizard Plus MiniPreps
DNA puri¢cation system, pfu polymerase, DNase I, luciferase plasmid
pGL-3 and assay system were from Promega (Madison, WI, USA).
GENECLEAN III kit was from BIO 101 (La Jolla, CA, USA). L-
Galactosidase plasmid (CMVL) was from Clontech Laboratories
(Palo Alto, CA, USA). TransIT transfection reagents were from Pan-
Vera (Madison, WI, USA). Dulbecco’s modi¢ed Eagle’s medium, ri-
bonuclease inhibitor and Opti-MEM medium were from Gibco BRL
(Grand Island, NY, USA). Fetal bovine serum was from Hyclone
Laboratories (Logan, UT, USA). Restriction enzymes and T4 poly-
nucleotide kinase were obtained from New England Biolabs (Beverly,
MA, USA) or TaKaRa (Kyoto, Japan). Antibodies against Sp1, Sp3
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and NF-1 were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and that against NF-YA was from Pharmingen (San Diego,
CA, USA). Rapid DNA ligation kit was from Boehringer Mannheim
(Mannheim, Germany).
2.2. Cell culture
Human epidermoid carcinoma A431 cells were grown at 37‡C
under air/CO2 (19:1) in 10-cm plastic dishes containing 10 ml of
culture medium consisting of Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum, 100 Wg/ml strepto-
mycin and 100 units/ml penicillin.
2.3. Construction of PHGPx gene promoter/luciferase reporter vector
The pGL3-basic vector, which contains a luciferase reporter gene
for the analysis of promoter activity of cloned fragments located im-
mediately downstream of a polylinker, was obtained from Promega.
The 0.4-kb promoter of PHGPx gene was ampli¢ed by PCR using a
modi¢ed promoter sense primer with an additional BglII restriction
site (5P-GAAGATCTTGGGGACACTTTTCTGCGAGTT-3P) and a
modi¢ed promoter antisense primer with an additional NcoI restric-
tion site (5P-CATGCCATGGCGCGGCGGGGCTGGGA-3P) using
genomic DNA of A431 cells as a template. The PCR fragments
were puri¢ed from 1% agarose gel using the GENECLEAN III kit.
Subsequently, the fragments were cleaved with BglII and NcoI and
cloned into pGL-3. Identi¢cation of isolated clones was con¢rmed by
DNA sequencing. One clone (pGP4-2), which contained the entire
0.4-kb promoter fragment, was chosen for further studies.
2.4. Preparation of promoter-deletion constructs
Human PHGPx gene promoter regions of various lengths were
prepared either by restriction enzyme digestion of pGP4-2 for the
preparation of pGP4-7, or by the PCR ampli¢cation method for the
preparation of pGP4-3, 4-4, 4-5, 4-8, 4-11, dFP3, dFP4 and dFP34.
The mutants at the sites of CCAAT (pGPdNFY) and AP-2
(pGPdAP2) were constructed by the site-directed mutagenesis method
as described by Higuchi et al. [17], and con¢rmed by DNA sequenc-
ing.
2.5. Transfection and reporter gene assays
Cells were replated 18 h before transfection at a density of 3U105
cells in 2 ml of fresh culture medium in a 3.5-cm plastic dish. For use
in transfection, 1 Wl of TransIT transfection reagent was mixed with
1 Wg of pGP luciferase plasmid and 0.5 Wg of L-galactosidase plasmid
in 1 ml of Opti-MEM medium and incubated for 30 min at room
temperature. Cells were transfected by changing the medium to 1 ml
of Opti-MEM medium containing the plasmids and TransIT trans-
fection reagent, followed by incubation at 37‡C in a humidi¢ed at-
mosphere of air/CO2 (19:1) for 4 h. After the change of Opti-MEM
medium to 2 ml of fresh culture medium, cells were incubated for an
additional 24 h and then the luciferase and galactosidase activities in
cell lysates were determined as described previously [18].
2.6. Gel-shift assay
Nuclear protein extracts were prepared from A431 cells by homog-
enization with a Dounce homogenizer, and double-stranded oligonu-
cleotides were prepared by the standard annealing method and labeled
with 0.2 WM [Q-32P]ATP using T4 polynucleotide kinase as probes [18].
The mixture of 2^3 Wg of the cell nuclear extracts and the radiolabeled
probe (2U104 c.p.m.) was incubated at room temperature for 30 min
and loaded on a 5% (w/v) polyacrylamide gel. Electrophoresis was
performed at a constant 200 V for 2 h. Gel was dried and autoradio-
graphed.
2.7. In vitro DNase I footprinting assay
In vitro DNase I footprinting experiments were mainly performed
according to the method of Lemaigre et al. [19]. Labeled probe (2^
3U104 c.p.m.) was incubated with 25^50 Wg of nuclear extracts for 30
min on ice. After digestion with 1^2 U of DNase I for 6 min on ice,
the degradation products were separated onto a 8% polyacrylamide,
7 M urea sequencing gel. The G and (G+A) chemical cleavage reac-
tions on the labeled probes were performed according to the standard
procedure [20].
3. Results
3.1. Expression of DNA constructs with 5P-deletion of human
PHGPx gene promoter in A431 cells
The promoter of human PHGPx gene (AC004151) lacks a
TATA-box. Each putative consensus sequences in the 5P-
£anking region of human PHGPx gene is enclosed in a box
as shown in Fig. 1. There are three putative Sp1 binding sites,
three AP-2 binding sites, two CCAAT-boxes, one glucocorti-
coid responsive element, and one cAMP responsive element in
the ¢rst 400 bp before the ATG start codon. To study the
transcriptional regulation of human PHGPx gene, the lucifer-
ase reporter vectors bearing various lengths of 5P-£anking
regions of human PHGPx were constructed as shown in
Fig. 2. Among these DNA constructs, pGP4-1 is a vector
bearing the luciferase reporter gene only. Cells were trans-
fected with various DNA constructs, and the basal expression
of luciferase activity in these vectors was studied. The results
are summarized in Fig. 2. No obvious expression was ob-
served in cells transfected with pGP4-8 (382 bp), and
pGP4-11 (346 bp), and there was very little expression in
pGP4-7 (3121 bp). However, a signi¢cant expression was
observed in luciferase vectors bearing a promoter longer
than 212 bp. The luciferase activity in 5P-deletion vectors ap-
parently is restricted in three regions covering from 3305
(pGP4-3) to 3237 bp (pGP4-4), from 3237 (pGP4-4) to
3212 bp (pGP4-5), and from 3212 (pGP4-5) to 3121 bp
(pGP4-7). The results indicated that the two putative binding
sites for GR and AP-2 residing in the region from 3400 to
3305 bp do not play any signi¢cant role since no di¡erence of
the luciferase activity between pGP4-2 and pGP4-3 was ob-
served. Although a signi¢cant decrease in luciferase activity
from pGP4-3 (3305 bp) to pGP4-5 (3212 bp) was found, no
well-de¢ned consensus binding sequence of transcription fac-
tor is present in the region from 3305 to 3212 bp. However,
presence of cis-elements for the binding of some unknown
transcription factors in this region is possible. In contrast,
multi-binding sites : two potential binding sites for Sp1, one
for AP-2, one for CCAAT-box (inverted sequence ‘ATTGG’),
and one for CRE binding site are present in the region from
3212 to 3121 bp. This region may be responsible for the
decrease in luciferase activity from pGP4-5 (3212 bp) to
pGP4-7 (3121 bp).
Fig. 1. Regulatory elements in human PHGPx gene. Each putative
consensus sequence in the 5P-£anking region of human PHGPx gene
is enclosed in a box. Abbreviations: GR, glucocorticoid responsive
element; AP-2, binding site of AP-2; Sp1, Sp1 binding site;
CCAAT, CCAAT-box; CRE, cAMP responsive element.
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3.2. Identi¢cation of the nuclear factors involved in the
expression of human PHGPx gene
The in vitro DNase I footprinting studies were performed
with a restriction fragment extending from 3400 to 31 bp.
Four protected areas on the fragment, designated FP1 (3246
to 3212 bp), FP2 (3202 to 3172 bp), FP3 (3170 to 3140
bp), and FP4 (3106 to 377 bp), were observed. FP3 region
covering from 3170 to 3140 bp played an essential role in the
regulation of PHGPx expression (Fig. 2). Three potential
binding sites for AP-2, CCAAT-box, and CRE are present
in this region. To further examine the protein binding proper-
ties to the FP3 region of promoter, DNA mobility shift and
super-shift assays were performed with an oligonucleotide ex-
tending from 3170 to 3140 bp (FP3). Synthetic oligonucleo-
tide FP3 was labeled with [Q-32P]ATP by T4 polynucleotide
kinase. When nuclear extracts from A431 cells were allowed
to react with FP3 probe, four retarded bands (a, b, c, and d)
were observed (Fig. 3B, lane 2). Among them, band b was the
Fig. 2. Transcriptional analysis of luciferase expression vectors bearing various lengths of human PHGPx promoter. Truncated promoter frag-
ment was ligated into a luciferase plasmid as described in Section 2. Numbers indicate the distance in base pairs from the translation start site.
A mixture of each pGP luciferase plasmid (1 Wg) and L-galactosidase plasmid (0.5 Wg) was transfected into A431 cells by the TransIT transfec-
tion method. The luciferase activity was normalized with the L-galactosidase activity. Values are means þ S.E.M. for three determinations.
Fig. 3. Determination of the binding of nuclear factors to FP3 (3170/3140) probe by gel-shift assay. DNA probe, FP3 (3170/3140), was la-
beled with [Q-32P]ATP as described in Section 2. A: DNA sequences of NF-Y, C/EBP, NF-1, Sp1 and AP2 consensus are indicated. The
CCAAT-box consensus sequences are denoted by arrows and thick lines. B: The radiolabeled FP3 probe was incubated with the nuclear ex-
tracts of A431 cells. Lane 1 is a free probe; lane 2, four retarded bands (a, b, c and d) are indicated; lanes 3^7, competitors NF-Y, C/EBP,
NF-1, Sp1 and AP-2 consensus were preincubated with nuclear extracts with a 50-fold molar excess of radiolabeled FP3 probe for 10 min at
room temperature, and then the radiolabeled FP3 probe was added. After 30 min at room temperature, the preparation was electrophoretically
separated.
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most signi¢cant. As there is a CCAAT-box in the oligonucleo-
tide FP3, study on the binding of CCAAT-box binding fac-
tors (CBFs) to the FP3 region was then followed. CBFs in-
clude a family of proteins including NF-Y/CP1, C/EBP, and
NF-1 [21,22]. To determine the speci¢city of protein binding,
the oligonucleotides that selectively bind CBFs, Sp1, and AP-
2 were used respectively in the competition experiments (Fig.
3A). Formation of band b was abolished by an oligonucleo-
tide with an NF-Y consensus, but not by C/EBP, NF-1 and
other competitors used (Fig. 3B). There are three putative
binding sites for AP-2, CCAAT-box, and CRE in the FP3
region. Three mutated oligonucleotides designated FP3m1,
FP3m2, and FP3m3 for AP-2, CCAAT-box, and CRE mu-
tants were synthesized and used as competitors, respectively
(Fig. 4A). Among these three mutants, mutant FP3m2 was
the only one that could not abolish the formation of band b
(Fig. 4B), indicating that band b is the only retarded band
formed by NF-Y protein interacting with the sequence of
CCAAT-box in FP3 probe. To further identify whether NF-
Y binds the FP3 probe, monoclonal antibody speci¢cally rec-
ognizing human NF-YA protein was used in the gel-shift
assay. The retarded band b was completely abolished by anti-
body against NF-YA but not by antibodies against Sp1, Sp3,
and NF-1, as determined with oligonucleotide FP3 as a probe
(Fig. 5). These results indicate that NF-Y was the major nu-
clear factor that bound the sequence of PHGPx gene pro-
moter from 3170 to 3140 bp.
3.3. Luciferase activity of mutants with internal truncation and
site-directed mutagenesis
To determine which of these putative binding sites in the
promoter region from 3164 to 375 bp is functionally relevant
to the expression of human PHGPx gene, e¡ect of the internal
truncation and site-directed mutagenesis was studied. Mutants
with the regions truncated from 3164 to 3115 bp
(pGPdFP3), from 3117 to 375 bp (pGPdFP4), and from
3164 to 375 bp (pGPdFP34) were prepared. Vectors with
mutations at the CCAAT-box (pGPdNFY), and at the AP-
2 site (pGPAP2) were obtained by site-directed mutagenesis
(Fig. 6A). Plasmids with internal truncation at the FP3 region
(pGPdFP3), FP4 region (pGPdFP4) and both FP3 and FP4
regions (pGPdFP34) eliminated the luciferase activity by 50%,
25%, and 70%, respectively (Fig. 6B). Plasmid with CCAAT-
box site-directed mutation (pGPdNFY) eliminated the lucifer-
ase activity by 50%, similar to the e¡ect induced by pGPdFP3.
However, no signi¢cant e¡ect was observed in pGPdAP2 with
a mutation at the putative AP-2 binding site in the FP4 re-
gion. These results indicate that the CCAAT-box in the FP3
region was essential for the basal expression of human
PHGPx gene.
4. Discussion
Several pieces of evidence were provided in this study to
indicate that the CCAAT-box in the promoter region from
Fig. 4. E¡ect of mutated competitors on the nuclear factors interacting with the radiolabeled FP3 probe. A: Wild-type and mutated FP3 se-
quence were used in competitive gel-shift analysis. B: The radiolabeled FP3 oligonucleotide was used as a probe and incubated with the nuclear
extracts of A431 cells. Lane 1 is a free probe; lane 2, four retarded bands (a, b, c and d) are indicated; lanes 3^6, competitors FP3m1,
FP3m2, FP3m3 and NF-Y consensus were preincubated with nuclear extracts with a 50-fold molar excess of radiolabeled FP3 probe for 10
min at room temperature, and then the radiolabeled FP3 probe was added. After 30 min at room temperature, the preparation was electro-
phoretically separated.
Fig. 5. E¡ect of antibodies to NF-Y, Sp1, Sp3 and NF-1 on the nu-
clear factors interacting with the radiolabeled FP3 probe. Radiola-
beled FP3 oligonucleotide was used as a probe and incubated with
the nuclear extracts of A431 cells. Lane 1, free probe; lane 2, nu-
clear extracts only; lanes 3^6, 0.2 Wg of each NF-Y, Sp1, Sp3 and
NF-1 antibodies was preincubated with nuclear extracts (2 Wg) for
2 h on ice, and then the radiolabeled FP3 probe was added. After
30 min at room temperature, the preparation was electrophoretically
separated.
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3155 to 3151 bp played a signi¢cant role in the basal expres-
sion of the human PHGPx gene in A431 cells. Firstly, the
promoter region, which was essential for the expression of
luciferase activity, was narrowed down to 91 bp ranging
from 3212 to 3121 bp with the aid of 5P-deletion constructs
of human PHGPx gene promoter. Secondly, in vitro DNase I
footprinting analysis revealed that there were transcription
factors binding on the region from 3170 to 3140 bp desig-
nated FP3 (data not shown). Thirdly, in gel-shift assays, the
NF-Y-speci¢c competitor and NF-YA monoclonal antibody
abolished the major nuclear protein bound to the FP3 region
(Figs. 3 and 5), and the competitor with the mutation at
CCAAT-box could not eliminate the binding of NF-Y protein
to the promoter DNA (Fig. 4). The results indicate that the
major retarded band was due to the binding of NF-YA to its
binding element in the promoter. Lastly, mutants with inter-
nal truncation and site-directed mutagenesis at the CCAAT-
box eliminated the luciferase activity of basal expression by
50%. We conclude that NF-Y is a speci¢c transcription factor
that binds the CCAAT-box of human PHGPx gene, and the
protein-DNA complex is essential for the basal expression of
human PHGPx gene. NF-Y is a heterotrimeric transcription
factor composed of three subunits (A, B, and C), and formed
a heterotrimeric complex with DNA [23,24]. Mutation at the
CCAAT motifs of promoter, including mouse K1 collagen
gene, mouse albumin gene, human multidrug resistance
gene, and human blood coagulation factor X gene, decreases
the basal promoter activity [25]. From the present study, NF-
Y speci¢cally bound the CCAAT-box in the promoter of
PHGPx gene. But not all the DNA oligonucleotides contain-
ing the CCAAT-box interacted with NF-Y. Among those as-
sociated with CBFs, only NF-Y/CP1 did, but not C/EBP and
NF-1 (Fig. 3), suggesting that in addition to CCAAT other
speci¢c nucleotides were also required for NF-Y binding.
Maiorino et al. [26] reported that 75Se-labeled PHGPx ex-
isted in the cytosol of several human tumor cell lines. A high
expression of PHGPx mRNA and its 12-lipoxygenase inhib-
itory activity was observed in several human cancer cell lines
including cervical carcinoma P26 cell, prostatic carcinoma
PC3 cell, breast cancer HTB-20 and lung cancer CL-1 cell
in addition to A431 cell [27]. Although the pathophysiological
signi¢cance of high level expression of PHGPx in cancer cells
is not understood, this enzyme as well as GPx-1 may play an
important role in protecting cells against oxidative damage.
Overexpression of PHGPx in a guinea pig cell line protects the
cells from injury induced by lipid hydroperoxides such as
dilinoleoyl phosphatidylcholine hydroperoxide and linoleic
acid hydroperoxide [28]. Overexpression of PHGPx suppresses
cell death due to the oxidative damage in rat basophile leu-
kemia cells [29]. Mice de¢cient in GPx-1 are healthy and fer-
tile and show no increased sensitivity to hyperoxia [30], but
show increased susceptibility to other oxidative stress-induc-
ing agents paraquat and hydrogen peroxide [31]. Asahi et al.
[32] used mass spectrometry to demonstrate that nitric oxide
and its derivatives directly oxidized Sec of bovine GPx-1 to
form a selenenyl sul¢de (Se-S) with a free thiol, leading to
inactivate the enzyme. On the other hand, the human GPx-1
gene contains two oxygen responsive elements (ORE1 and
ORE2) in the 5P-£anking promoter region, which are respon-
sive to the oxygen tension in primary cultured human ventric-
ular cardiomyocytes [33]. In addition, after exposure to phor-
bol 12,13-dibutyrate (PdBu), GPx-1 in cultured human
endothelial cells undergoes transcriptional activation via the
AP-1 interaction with the TRE sites in the GPx-1 promoter
[34].
In the present study of PHGPx gene, neither ORE nor TRE
exists in the 5P-£anking region, but CCAAT-box of the prox-
imal promoter, bound to NF-Y/CP1, is essential for the basal
Fig. 6. E¡ect of internal truncation and site-directed mutation of CCAAT-box on the promoter activity. A: The sequence of wild-type (WT)
promoter and the mutated nucleotides in mutant constructs are indicated. B: A mixture of each pGP luciferase plasmid (1 Wg) and L-galactosi-
dase plasmid (0.5 Wg) was transfected into A431 cells by the TransIT transfection method. The luciferase activity was normalized with the L-
galactosidase activity. Values are means þ S.E.M. for three determinations. (**P6 0.01; ***P6 0.001 compared with pGP4-2.)
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expression of human PHGPx gene in A431 cells. Recently,
Schnurr et al. [35] found that IL-4 and IL-13 can up-regulate
12/15-lipoxygenase and simultaneously down-regulate
PHGPx, and then create an oxidative environment inside
the human lung carcinoma cells A549. These ¢ndings may
be of pathophysiological importance for disorders associated
with reduction-oxidation reactions such as cancer, atheroscle-
rosis, and in£ammation. Although the selenocysteine residue
in the active site of selenoproteins is important to catalyze the
reduction-oxidation reactions [32], the other signi¢cant role of
CCAAT-box in the PHGPx gene promoter on the high gene
expression in several cancer cells and its role on the protection
to oxidative damage should be considered and further eluci-
dated.
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